Preparation & Measurement Guide

Retatrutide 40mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Retatrutide 40mg vial.

Research use only Educational summary of a commonly documented convention. Not approved for human use.
Vial Size Retatrutide 40mg
Preparation 2mL bacteriostatic water
Concentration 20mg/mL after preparation
Documented Convention 2-12mg once weekly

1. Preparation and Measurement

Retatrutide 40mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 20mg/mL. On a U-100 syringe, each unit contains 200mcg.

40mg / 2mL = 20mg/mL
1 U-100 unit = 0.01mL = 200mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in phase 2 research. Frequency: once weekly.

Period Documented amount Measurement
Weeks 1-4 2mg once weekly 0.1mL / 10 units
Weeks 5-8 4mg once weekly 0.2mL / 20 units
Weeks 9-12 8mg once weekly 0.4mL / 40 units
Weeks 13+ 12mg once weekly 0.6mL / 60 units

Vial estimate: One 40mg vial contains approximately 20 administrations at the first listed amount or 3 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Retatrutide 40mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Retatrutide is an investigational triple receptor agonist studied in phase 2 trials. It is not an approved medicine, and later-stage research may use different designs or conclusions.

The table records a phase 2-style escalation for educational comparison. It is not a prescribing schedule or evidence that a laboratory vial is suitable for human use.

Primary Research and Regulatory References

  1. Retatrutide phase 2 obesity trial
  2. Retatrutide phase 2 diabetes trial
  3. Retatrutide phase 2 trial registry

Research Materials

Review Retatrutide 40mg Product Information

← Back to Dosage Protocols

Research-use disclaimer: Retatrutide 40mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.